Analysts Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) PT at $60.65

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has received a consensus rating of “Moderate Buy” from the nineteen analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $60.65.

IONS has been the topic of several research reports. BMO Capital Markets lowered shares of Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $67.00 to $60.00 in a report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price objective on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Monday, August 26th. StockNews.com cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Piper Sandler lowered their price objective on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, Wells Fargo & Company decreased their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th.

Ionis Pharmaceuticals Trading Up 0.2 %

NASDAQ IONS opened at $34.01 on Tuesday. Ionis Pharmaceuticals has a one year low of $33.33 and a one year high of $54.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The business has a 50 day simple moving average of $38.70 and a 200 day simple moving average of $42.47. The stock has a market capitalization of $5.37 billion, a P/E ratio of -13.94 and a beta of 0.39.

Insider Activity at Ionis Pharmaceuticals

In related news, CEO Brett P. Monia sold 6,630 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total transaction of $252,271.50. Following the completion of the sale, the chief executive officer now owns 167,393 shares of the company’s stock, valued at approximately $6,369,303.65. This trade represents a 3.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Eric Swayze sold 1,194 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the transaction, the executive vice president now owns 33,713 shares in the company, valued at $1,278,396.96. This represents a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,197 shares of company stock valued at $315,310. Corporate insiders own 2.71% of the company’s stock.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several hedge funds have recently bought and sold shares of IONS. Mather Group LLC. lifted its stake in Ionis Pharmaceuticals by 35.8% during the second quarter. Mather Group LLC. now owns 911 shares of the company’s stock worth $39,000 after purchasing an additional 240 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in Ionis Pharmaceuticals by 3.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock worth $363,000 after buying an additional 261 shares during the last quarter. Nicollet Investment Management Inc. boosted its stake in Ionis Pharmaceuticals by 1.5% in the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock worth $817,000 after buying an additional 294 shares in the last quarter. Amalgamated Bank grew its position in Ionis Pharmaceuticals by 3.1% during the third quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock valued at $399,000 after acquiring an additional 300 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after acquiring an additional 303 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.